Dana-Farber Privacy Statement
Your privacy is important to us, so we operate the site by the following principles:
You may use our site without disclosing personally identifiable information. We want to be clear that we will not obtain such information about you unless you choose to submit it to us. If you supply personally identifiable information (such as name, address or telephone numbers) for various purposes on this site, we only use the information for that purpose (such as to provide the service or information you have requested).
Dana-Farber takes every precaution to protect our users' information. When a registration/order form asks users to enter sensitive information (such as credit card number and/or diagnosis), that information is encrypted and is protected with the best encryption software in the industry-SSL.
Should you electronically request a referral to a Dana-Farber physician, we will use the information you submit to arrange for care where appropriate. While we use SSL encryption to protect sensitive information online, we also do everything in our power to protect user-information off line. Our software and hardware is configured to provide maximum security.
Information Collection and Use
Dana-Farber is the sole owner of the personal medical information collected on this site. We will not sell, share, or rent this information to others. Dana-Farber occasionally trades its contributor mailing lists with other non-profit organizations. This process saves us money and is carefully monitored and one may always opt out.
In the News
Poster presentation, PDx Platform of High Grade Serous Ovarian Cancer, at the 2014 AACR General Meeting in San Diego by Sangeetha Palakurthi PhD, Head of Cancer Biology and Pharmacology.
Oral presentation, Serial monitoring of EGFR mutations in plasma NSCLC patients by ddPCR, at the 2014 AACR General Meeting in San Diego by Cloud Paweletz PhD, Head of Translational Research Lab.
Findings from the Translational Research Lab within the Belfer Institute demonstrate that circulating DNA from non-invasive plasma samples is a promising biomarker to monitor response and predict resistance in the clinic.
Belfer scientists collaborate with W. Kaelin MD , to demonstrate that the Ikaros family of transcription factors are key downstream mediators of the efficacy of thalidomide-like drugs.